Načítá se...
CADD-49. IDENTIFICATION AND VALIDATION OF AZOLES AS HK2 INHIBITORS IN GLIOBLASTOMA IN VITRO AND IN VIVO
BACKGROUND: Hexokinase I and 2 (HK1/HK2) catalyze the first committed step in glucose metabolism, ensuring a sustained glucose concentration gradient. Glioblastomas (GBMs) over-express HK2, and we have previously shown that its loss sensitizes GBM cells to treatment. In this study, we have conducted...
Uloženo v:
| Vydáno v: | Neuro Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Oxford University Press
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6216877/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.1177 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|